Autres langues Bioseek PLC

Actions

ATD

GB0009231639

Recherche biotechnologique et médicale

Cours en clôture London S.E.			Varia. 5j.	Varia. 1 janv.
- ^GBX	-.--%		-.--%	-

Autres langues

19/05/12	Asterand Plc : Interim Management Statement
30/04/12	Asterand Plc : Financial Results Statement
28/03/12	Asterand Plc : Asterand's Subsidiary BioSeek Extends Collaboration with Merck Serono
13/03/12	Asterand Plc : BioMAP? Profiling Provides Insights into Toxicity of Nanomaterials, Failed Drugs and Environmental Chemicals
12/03/12	Asterand Plc : BioMAP® Profiling Provides Insights into Toxicity of Nanomaterials, Failed Drugs and Environmental Chemicals
06/03/12	Asterand Plc : Update on Formal Sale Process
31/01/12	Asterand Plc : Asterand Subsidiary BioSeek and US EPA Expand ToxCastTM Collaboration
31/01/12	Asterand Plc : Asterand Subsidiary BioSeek and US EPA Expand ToxCast? Collaboration
05/01/12	Asterand Plc : Update on Formal Sale Process
30/11/11	Asterand Plc : Asterand's Subsidiary BioSeek Achieves A Research Milestone In Drug Discovery Collaboration With Ono
18/11/11	Asterand Plc : Update on Formal Sale Process
18/11/11	Asterand Plc : Interim Management Statement
08/11/11	Asterand Plc : Asterand Receives Contract Extension from NCI
08/11/11	Asterand Plc : Update on BioSeek Loan Notes
24/10/11	Asterand Plc : Commencement of Formal Sales Process
19/10/11	Asterand Plc : Board Changes
23/09/11	Asterand Plc : Contract Change
31/08/11	PHARMAGENE : Board Changes
19/08/11	PHARMAGENE : Notification of Interim Results
29/07/11	PHARMAGENE : Board Changes
08/06/11	PHARMAGENE : AGM Statement and Proxy Voting Results
31/03/11	PHARMAGENE : Asterand Awarded Key Patents on the BioMAP Technology
29/03/11	PHARMAGENE : Asterand and 5AM Solutions Enter a Preferred Partnership Agreement
04/10/10	PHARMAGENE : Asterand Awarded Contract Totaling up to $24.3 million with the National Cancer Institute
23/09/10	PHARMAGENE : Asterand's Subsidiary BioSeek Signs Agreement with Cellzome